Mucosal Cytokine Profiles Across Different Therapies in Ulcerative Colitis During Endoscopic Remission
Background Although advanced therapies for ulcerative colitis target distinct immune pathways, it remains unclear whether these agents differentially modulate mucosal cytokine expression in patients with deep mucosal healing. Aims To investigate mucosal cytokine profiles across colonic segments and treatments in patients with ulcerative colitis in endoscopic remission. Methods This observational study included 113 patients with ulcerative colitis in clinical and endoscopic remission (Mayo endoscopic subscore of 0). Biopsy specimens from the rectum, sigmoid colon, and cecum were analyzed by reverse transcription quantitative polymerase chain reaction for mRNA expression of 21 cytokines. Expression levels were compared across six treatment groups: 5-aminosalicylic acid, azathioprine, anti-tumor necrosis factor-α antibodies, vedolizumab, ustekinumab, and tofacitinib. Global cytokine patterns were evaluated using heatmaps and principal component analysis. Results Of the 21 cytokines analyzed, only IL-8 and IL-17A showed treatment-related differences. In rectal biopsy specimens, IL-8 expression was lower in the anti-tumor necrosis factor-α group than in the vedolizumab and tofacitinib groups, whereas IL-17A expression was lower in the ustekinumab group than in all other treatment groups. In the sigmoid colon, IL-17A expression was also lower in the ustekinumab group, whereas no significant treatment-related differences were observed in the cecum. Conclusions Among patients with ulcerative colitis in deep endoscopic remission, mucosal cytokine expression remains heterogeneous and is largely comparable across different therapeutic agents. IL-17A expression was selectively reduced in patients treated with ustekinumab, consistent with IL-23/Th17 pathway inhibition. Endoscopic healing may not necessarily reflect immunological uniformity in the colonic mucosa. Trial registration: UMIN000017990, registered June 20, 2015.
Authors
- Reo Kobayashi (ORCID: https://orcid.org/0000-0002-0910-6915)
- Makoto Tanaka (ORCID: https://orcid.org/0000-0002-0798-9689)
- Mariko Kajiwara
- Yuji Naito (ORCID: https://orcid.org/0000-0003-4749-4389)
- N. Iwai (ORCID: https://orcid.org/0000-0002-6943-1605)
- Hiroaki Kitae (ORCID: https://orcid.org/0000-0002-7103-8191)
- Tomohisa Takagi (ORCID: https://orcid.org/0000-0002-6119-4828)
- Mitsuo Kishimoto (ORCID: https://orcid.org/0000-0002-7407-9044)
- Katsura Mizushima (ORCID: https://orcid.org/0000-0001-5481-7022)
- Kohei Asaeda
- Ken Inoue (ORCID: https://orcid.org/0000-0002-6383-0576)
- Ryohei Obata
- Osamu Dohi (ORCID: https://orcid.org/0000-0002-0498-0144)
- Kazuhiko Uchiyama (ORCID: https://orcid.org/0000-0001-5210-167X)
- Yuma Hotta
- Kazuhiro Katada (ORCID: https://orcid.org/0000-0002-9629-9507)
- Junki Yumoto
- Eiki Murakami
- Haruna Horikawa
- Masato Hirohashi
Institutions
- Kyoto Prefectural University of Medicine (JP)
- Takeda Hospital (JP)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-19
- DOI
- https://doi.org/10.21203/rs.3.rs-11602219/v1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- preprint